CAMBRIDGE, England, November 20 Stem CellSciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisationof stem cells and stem cell technologies, has signed a Master ServiceAgreement of up to five years with Pfizer Limited, the UK operating unit ofthe global research-based pharmaceutical company Pfizer, Inc. (NYSE: PFE).Under the terms of the agreement, SCS will provide research services, celllines, media and reagents to support Pfizer's R&D efforts in this importantfield.
Dr Alastair Riddell, CEO of SCS, said, "The opening of Pfizer's newregenerative medicine research facility in Cambridge, UK, last week is veryimportant for stem cell research and reinforces the UK's position as aninternational centre of excellence. We are therefore very pleased to be ableto support Pfizer's efforts to advance biomedical research under our newagreement."
The Pfizer regenerative medicine unit will be led by Chief ScientificOfficer, Ruth McKernan, PhD, who said, "I'm very excited to lead this newresearch unit. While there is still a lot to understand about how stem cellscan be used therapeutically, we believe it is one of the most promising areasof scientific research. Building successful partnerships with companies suchas Stem Cell Sciences will be important for us."
About Stem Cell Sciences plc
Stem Cell Sciences (SCS) is an international research and developmentcompany focusing on the commercial application of stem cell biologytechnologies for drug discovery and regenerative medicine research. Stem CellSciences is now focussing on building revenues through the sale of products,collaborative research and licensing deals with international biotechnologyand pharmaceutical companies.
Stem Cell Sciences has a substantial portfolio of patents and patentapplications in both adult and embryonic stem cell fields. The Company hasbeen active in the stem cell research field since 1994, principally focusedon technologies to grow, differentiate, and purify adult and embryonic stemcells. These include technologies to permit the generation of highly purifiedstem cells and their differentiated progeny (specialised tissue cell types)for use in genetic, pharmacological and toxicological screens. Moreover,these technologies may be able to provide pure populations of appropriatecell types for transplantation therapies in the future.
The Company has its main research base and headquarters in Cambridge, UKwith a second research base in Monash near Melbourne, Australia and abusiness development office in San Francisco, USA.
For further information on the company please visit:http://www.stemcellsciences.com.For further information, please contact: Stem Cell Sciences plc (United Kingdom), Alastair Riddell, CEO, Tim Allsopp, Chief Scientific Officer, +44(0)1223-499160; Stem Cell Sciences pty ltd (Australia), Paul Bello, Operations Manager, +61(0)400-500-495; Citigate Dewe Rogerson (For SCS, UK), Mark Swallow / Emma Palmer Foster / Amber Bielecka, +44(0)20-7638-9571; Talk Biotech (For SCS, Australia), Fay Weston, Director, +61(0)422-206-036; Daniel Stewart & Company (NOMAD to SCS, UK), Simon Leathers / Simon Starr, +44(0)207-776-6566
SOURCE Stem Cell Sciences plc